ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

MET

MET proto-oncogene, receptor tyrosine kinase · also HGFR, RCCP2, DFNB97 · IPT domain containing

25 programs in company-led studies act on MET, from 18 companies: 9 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
cabozantinibruleExelixisinhibitorphase 43610 runningKDRChEMBL
CrizotinibrulePfizerinhibitorphase 4312 runningALK, EML4, MST1R, NPM1, ROS1NCIt
telisotuzumab adizutecanAbbVie–phase 31818 running–the company's pipeline
zanzalintinibruleExelixisinhibitorphase 31715 runningAXL, KDRNCIt
amivantamabruleJohnson & Johnson–phase 31613 runningEGFRNCIt
vebreltinibruleBeijing Pearl Biotechnology Limited Liabilityinhibitorphase 394 running–NCIt
glumetinibruleHaihe Biopharmainhibitorphase 384 running–NCIt
bafisontamabruleShanghai EpimAb Biotherapeutics–phase 354 runningEGFRNCIt
HS-20117Hansoh Pharmaceutical Group–phase 333 runningEGFRthe company's pipeline
vilzemetkibSino Biopharmaceuticalinhibitorphase 382 runningAXLthe company's pipeline
dalmelitinibHansoh Pharmaceutical Groupinhibitorphase 372 running–a judged reading
SHR-1826Jiangsu HengRui Medicine–phase 277 running–the company's pipeline
TQB2922Sino Biopharmaceutical–phase 255 runningEGFRthe company's pipeline
pamvatamigruleBetta Pharmaceuticals–phase 254 runningEGFRNCIt
c-Met Inhibitor ANS014004ruleAvistone Biotechnologyinhibitorphase 233 running–NCIt
TQB6411Sino Biopharmaceutical–phase 233 runningEGFRthe company's pipeline
Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703ruleChong Kun Dang Pharmaceutical–phase 211 running–NCIt
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Cayman–phase 211 runningEGFRNCIt
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruleTavotek Biotherapeutics–phase 122 runningEGFR, VEGFANCIt
HS-20122Hansoh Pharmaceutical Group–phase 122 runningEGFRthe company's pipeline
ABBV-253AbbVie–phase 111 running–the company's pipeline
Anti-c-Met Antibody-drug Conjugate YL211MediLink Therapeutics (Suzhou)–phase 111 running–the company's pipeline
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsoninhibitorphase 111 runningEGFRa judged reading
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicines–phase 111 runningEGFRNCIt
HLX48Fosun Pharma–phase 111 runningEGFRthe company's pipeline

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.